Back to Results

A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Interested in this Trial?

Contact Us

Trial Status Completed

Trial Identifier

NCT00299000

Condition

MPS VI, Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome

The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.

Trial Summary

The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.

Eligibility Criteria

Birth Sex

All

Age

Up to 1 Year

Healthy Volunteers

No

Drug/Treatment:

Naglazyme

Phase:

Phase 4

Study Type:

Interventional

Number of Participants:

4

Study Started:

2006-05

Study Updated:

2011-07-22

Trial Locations

  • Children's Hospital Los Angeles

    Los Angeles, California, United States

  • Children's Hospital Oakland

    Oakland, California, United States

  • Hospital Femme Mere Enfant Centre

    Lyon, , France

  • Hospital PediAtrico de Coimbra

    Coimbra, , Portugal

Inclusion Criteria

  • Signed informed consent by a parent or legal guardian
  • Parent or legal guardian willing and able to comply with all study procedures
  • Equal to or greater than 36 weeks estimated gestational age by physical exam at birth
  • Has a diagnosis of MPS VI based on a documented prenatal diagnosis or fibroblast or leukocyte N-acetylgalactosamine 4-sulfatase (ASB) enzyme activity level of less than 10% of the lower limit of the normal range of the measuring laboratory
  • Is less than one year of age
  • Has no evidence of skeletal dysplasia based on physical exam

Exclusion Criteria

  • Parent of legal guardian perceived to be unreliable or unavailable for study participation
  • Use of any investigational drug within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
  • Has concurrent disease or condition that would interfere with study participation or safety (i.e., has previously undergone hematopoietic stem cell transplantation such as bone marrow or cord blood transplantation, or major organ transplantation)
  • Any condition that, in the view of the principle investigator, renders the subject at high risk from treatment compliance and/or completing the study
  • Has known hypersensitivity to Naglazyme
  • Has previously received Naglazym

Contact BioMarin Clinical Trials

Please complete and submit the following form to express interest in participating and request more information about one of our active clinical trials

*required fields

"*" indicates required fields

Please select the trial that you are interested in from the dropdown below. Note that this list only includes currently active trials. If you cannot find the trial you are seeking, please enter the study identifier and title in the comments box below, along with any other details you would like us to know to help address your inquiry.
Consent*
Consent*
For more Information about BioMarin's privacy obligations or to exercise your privacy rights, please visit BioMarin's Data Privacy Center.
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form

What’s Next?

Visit the following links to learn more about clinical trials.

Discuss this trial with your care team.

You may wish to print this page to share the details with your healthcare providers and discuss whether you may be eligible.

Print

Get in touch.

Contact Us